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Abstract 
Triple Negative Breast Cancer (TNBC), an aggressive form of breast cancer, has abnormal 
therapeutic results; leading to the need for unique treatment methods. Currently TNBC has no 
specific targeted therapy and has limited response to other chemotherapeutics. Plant extracts 
have shown to be useful as chemopreventive agents due to their disruption of pro-survival and 
proliferative mechanisms on cancer cells. Rosehip extracts have shown anti-proliferative activity 
against cancer cells in vitro. We hypothesized that rosehip extracts will inhibit cell proliferation 
in triple negative breast cancer cell lines at varying concentrations. Therefore, this study was 
designed to investigate the effect of rosehip extracts as anti-proliferative agents in African-
American TNBC cell lines (HCC1806 and MB157), luminal breast cancer cell lines (HCC70 and 
HCC1500), and a primary breast cell line (AG11132) as a model for non-cancerous tissues. To 
determine the inhibitory role of rosehip extracts in cell proliferation, MTT assays were 
conducted, following treatment with varying concentrations of rosehip extracts (1mg/ml, 
250ug/ml, 25ug/ml, and 25ng/ml) for 48 hours. The data suggests that rosehip extracts, can 
significantly decrease cell proliferation. Western blot analysis was used to investigate which 
signaling pathway rosehip extracts were affecting. Western blot analysis suggests that rosehip 
extracts are inhibiting p70 S6 kinase phosphorylation and its ability to act as a kinase for S6 
ribosomal protein. Preliminary data suggests that Rosehip Methanol extracts may have a 
synergistic effect with Doxorubicin, a known chemotherapeutic, in cell lines lacking the 
progesterone receptor. Overall, rosehip extracts decrease cell proliferation in African-American 
breast cancer cell lines, by decreasing phosphorylation along the PI3K signaling pathway. 
Rosehip extracts may have the potential to serve as a neoadjuvant therapeutic in the 
chemotherapeutic realm.
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CHAPTER 1 
Introduction 
The public health and social science sector examine diseases to identify if there are 
indications of a difference in environment, access to, utilization of and quality of care. The 
disproportionate burden of disease, known as health disparities, display a health outcome which 
deserves attention (Chu, Miller, & Springfield, 2007). Breast cancer is the most frequently 
diagnosed cancer in women. While Caucasian women are more likely to be diagnosed with 
breast cancer, African-American women are more likely to die from the disease (Carey et al., 
2006). This health disparity has become the leading cause of cancer death among women in 
economically developing countries (Jemal et al., 2011). Varying risk factors play a role in who 
becomes diagnosed with breast cancer. Race and ethnicity appear to play a large role in 
determining if an individual will develop breast cancer. In comparison to other ethnic groups, 
Caucasian women and African-American women have higher incidence rates. While Caucasian 
women are more likely to develop breast cancer, African-American women are more likely to 
die from the disease. African-American women are also more likely to be diagnosed before the 
age of 40 (Carey et al., 2006). In conjunction with developing the disease at such an early age, 
African-American women are more likely to be diagnosed with aggressive late stage tumors.  
Triple negative breast cancer (TNBC) is characterized by cells that lack the estrogen and 
progesterone receptors and lacks an overexpression of human epidermal receptor 2 (HER-2) 
(Dawood, 2010). The absence of these three vital hormone receptors causes TNBC to have 
unique therapeutic results leading to the need for unique treatment methods.  These receptors are 
expressed in normal breast tissue and other forms of breast cancer. Each receptor plays a role in 
the normal development of breast tissue. The HER-2 surface protein participates in signal 
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transduction pathways that aid in differentiation and growth.  This subtype of breast cancer 
currently has no specific targeted therapy and there is a large amount of cases in premenopausal 
women as well as African-American women.  
The reasons associated with breast cancer disparity are not entirely understood. The 
progression of breast cancer is believed to be a multistep process. This process includes the 
activation and inactivation of several different genes, such as Her2/neu (Belguise, Kersual, 
Galtier, & Chalbos, 2005).  Her2/neu overexpression plays a role in the aggressiveness of breast 
cancer. The mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) 
are two major pathways involved in proliferation and survivalWhen this gene is overexpressed, 
the MAPK and PI3K  cell signaling pathways are stimulated (Hynes & MacDonald, 2009). The 
increased activation of genes involved in cell proliferation, differentiation and other biological 
process can be due to improper regulation and activation of transcription factors, such as the 
activator-factor 1(AP-1)  (Young & Colburn, 2006). AP-1 is plays a role in cell proliferation 
through activation of the MAPK pathway. This transcription factor is linked to transformation 
when there are elevated levels in the cell (Young & Colburn, 2006). The discovery that mitogen-
induced metabolic processes may be regulated by serial phosphorylation and decreasing 
phosphorylation events has been the attention of signal transduction studies for decades (Pullen 
& Thomas, 1997). This pathway is responsible for cellular processes such as cell proliferation, 
growth, apoptosis, and cytoskeletal rearrangement  (Chang H Song, 2010). Components of the 
phosphatidylinositol 3-kinase signaling are deregulated in different human cancers. One 
component that is deregulated within the PI3K pathway is the p70 S6 kinase. The activity of p70 
S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker 
and pseudosubstrate domains. This mitogen is required for cell growth and G1 cell cycle 
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progression (Pullen & Thomas, 1997). The intracellular catalytic domain of the HER-2 receptor 
can be phosphorylated by the formation of homodimeric and heterodimeric kinase active-
complexes. This then  leads to activation of signaling pathways that promote proliferation or 
survival of breast cancer cells (Chang H Song, 2010). . Mitogens within the MEK/ERK signaling 
pathway function by transmitting signals from receptors to regulate gene expression and can also 
play a role in the prevention of apoptosis. This pathway interacts with the PI3K pathway to 
regulate growth in forms of tumorigenesis (McCubrey et al., 2006).  AKT, p70 S6 kinase, and 
ribosomal protein S6 are among the most important of the downstream  molecules found  in 
these pathways (Chang H Song, 2010).  Previously it was shown that rosehip extracts diminish 
AKT and MAPK signaling mechanisms in human brain tumor cell line (Cagle et al., 2012). 
However, the effect of rosehip extracts on these mitogens has yet to be studied in breast cancer 
cell lines and can show to be useful in finding a potential alternative treatment method for 
TNBC.  
Studies have shown natural products, such as plants, can have a chemopreventive effect 
on cancer progression. Epidemiological studies have suggested  that specific dietary 
consumption patterns are associated with increased risks of developing cancer at several sites 
(Tumbas et al., 2011).  Antioxidants are capable of scavenging free radicals, which can oxidize 
major biological macromolecules in cells and tissues (Wang, Meckling, Marcone, Kakuda, & 
Tsao, 2011). The concept that consumption of antioxidant rich foods may prevent cancer or 
improve treatment has been supported by some studies (Gao, Björk, Trajkovski, & Uggla, 2000). 
The studies mentioned above indicate that vitamins and certain phytochemical antioxidants 
including flavonoids and carotenoids are effective against proliferation of human colorectal, 
breast and stomach cancer cells  (Wang et al., 2011). Plant extracts have been used as 
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chemopreventive agents due to their mechanistic actions on cancer cells (Amin, Kucuk, Khuri, & 
Shin, 2009). Rosehip fruits have shown potent anti-proliferative activity against colon, breast, 
and cervical cancer cells in vitro. Rosehips are high in vitamin C (Tumbas et al., 2011) causing 
this pseudo fruit to be rich in ascorbic acid, phenolic components, and carotenoids (Chrubasik, 
Roufogalis, Müller-Ladner, & Chrubasik, 2008). These high antioxidant contents cause rosehips 
to have high antioxidant activities. Studies have shown  rosehips are useful in treating arthritis 
due to its anti-inflammatory and antioxidant effects (Andersson, Berger, Hogberg, Landin-
Olsson, & Holm, 2011). These dietary antioxidants may contribute to the protection of 
biologically important cellular components. Antioxidants function by reacting with free oxygen 
radicals and action as reducing agents to induce production of anti-oxidative enzymes. This 
contributes to the inhibitory capacity against cell proliferation caused by these antioxidants (Su 
et al., 2007).  Studies have shown that the Vitamin C and flavonoids found in rosehips are 
responsible for the antioxidant activity associated with it (Wang et al., 2011). However, it is the 
polyphenols found within this plant that is responsible for the anti-proliferative activity (Wang et 
al., 2011).  Crude rosehip extracts inhibited cell proliferation activity without inducing apoptosis 
in glioblastomas in vitro (Cagle et al., 2012). To our knowledge, the anti-proliferative effects on 
cell proliferation in African-American triple negative breast cancer have not yet been tested.   
The objective of the present study is to determine the effects of crude rosehip extracts on 
cell proliferation and cell migration in triple negative breast cancer cell lines, and to identify 
signaling pathways responsible for those effects. We hypothesized that rosehip extracts inhibit 
cell proliferation in triple negative breast cancer cell lines at varying concentration levels by 
blocking the AKT and Mek/Erk1/2 signaling pathways. Within this study, three objectives were 
used to determine the role of rosehip extracts in African-American TNBC cell lines and luminal 
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breast cancer cell lines: 1) determine the effect of rosehip extracts on cell proliferation in 
African-American breast cancer cell lines (HCC70, HCC1500, HCC1806 and MB157); 2) to 
identify the signaling  pathways responsible for mediating rosehip extract effects on cell 
proliferation in African-American breast cancer cell lines; 3) Examine whether the efficacy of 
Doxorubicin, a known breast cancer chemotherapeutic, is increased when cells are pre-treated 
with rosehip extracts. Due to the therapeutic challenges that triple negative breast cancer patients 
face this study can lead to new and innovative therapeutic options. Although the usefulness of 
rosehip extracts in breast cancer cell studies remains unknown, exploring the functional role of 
these extracts can be helpful in discovering potential clinical uses. The research presented here is 
thus significant, because it will lead to a better understanding of novel mechanisms of rosehip 
extracts and how they can effect cell proliferation in triple negative breast cancer cell lines. This 
research gives insight to rosehip extracts serving as a homeopathic treatment. 
. 
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CHAPTER 2 
Literature Review 
2.1 Breast Cancer 
Breast cancer is defined as a malignancy that forms in tissues of the breast usually within 
the ducts, which are the tubes that carry milk to the nipple. It can also affect the lobules, which 
are the glands that make milk. Breast cancer can either be invasive or noninvasive. Invasive 
forms of the cancer spread from the milk duct or lobule to other tissues of the breast. Breast 
cancer has the ability to affect both men and women; however, men being diagnosed with breast 
cancer are a rarity. The causality of breast cancer is still poorly understood; however there have 
been links to lifestyle choices or habits to its increased risk (Reddy, Odhav, & Bhoola, 2003).  
Risk factors may also include age, genetics, exposure to radiation, and family history of cancer 
(Yang et al., 2007).  Women with longer menstrual histories are also at a greatest risk. Studies 
have shown that women that start their menstrual cycles early in life or end later in life are at a 
greater risk of being diagnosed with breast cancer (Ursin et al., 2005).   
Breast cancer, a heterogeneous disease, is composed of various recognized biological 
subtypes (Carey et al., 2006). The classification of these subtypes of the disease is able to assist 
in prognostication and targeting of treatment. The classification of subtypes is determined by the 
presence of certain identifiable markers. Estrogen positive tumors fall in the category of being 
either luminal A or luminal B, while estrogen negative tumors may be basal-like or human 
epidermal growth factor receptor 2 (HER-2) positive/estrogen receptor negative (Carey et al., 
2006). Luminal A tumors are estrogen receptor and progesterone receptor positive, HER-2 
negative, and express low levels of Ki-67. Luminal B tumors have similar characteristics to the 
luminal A tumors; however, these tumors express high levels of Ki-67 and can be either HER-2 
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negative or positive.  The genes associated with this subtype of tumors indicate higher 
proliferation rates in comparison to luminal A tumors (Goldhirsch et al., 2011). Basal-like 
tumors show low expressions of HER-2 and the estrogen receptor. This subtype has high 
expression of genes which are characteristic of the basal epithelial cell layers. 80% of triple 
negative tumors overlap with the basal-like subtype, even though triple negative tumors do 
express some unique characteristics of its own (Goldhirsch et al., 2011).  
Breast cancer diagnosis is a critical prelude to treatment options in patients. Tools such as 
clinical breast exams and mammography are used to diagnosis women with breast cancer. These 
diagnostic methods are part of early detection screening. There are several benefits associated 
with early detection screening such as ability to detect the disease at an early age. By detecting 
the disease at an early age, patients are less likely to have aggressive forms of the disease. This is 
beneficial to patients allowing them to have a wider range of treatment options such as less 
aggressive surgery and adjuvant therapy (Dunn, Agurs-Collins, Browne, Lubet, & Johnson, 
2010). 
 There are several factors which play a role in a patient’s chances of survival, such as 
stage at diagnosis, age, socioeconomic factors, obesity, and tumor characteristics. The five year 
survival rate is lower in women who have a more advanced stage of the disease when diagnosed. 
Women who are diagnosed before age forty have a lower survival rate in comparison to women 
diagnosed at forty or older  (Newman et al., 2006). Several studies have shown a poorer 
prognosis for women diagnosed at a young age (≤35). Although these women are in the 
minority, they typically have larger more aggressive tumors (El Saghir et al., 2006).  Although 
the rate of survival has increased over the years, there is still a very large racial gap between 
Caucasian women and African-American women. Studies have shown poverty and a lack of 
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health insurance are associated with a lower survival rate (Newman et al., 2006).  Obese patients 
are 30% more likely to die from breast cancer in comparison to those who maintain a healthy 
weight. This is shown in several studies which suggest that exercise throughout treatment can 
improve the outcome of the disease  (Dunn et al., 2010). Patients with estrogen receptor positive 
and progesterone receptor positive tumors have the most favorable prognosis. The presence of 
the estrogen and progesterone receptors allows the patients to have favorable responses to 
hormonal therapies. However, patients with triple negative tumors or tumors with HER-2 
overexpression have a less favorable prognosis (Dunnwald, Rossing, & Li, 2007). 
It is not completely understood why women under the age of 35 have poorer prognosis; 
however, there are several studies that have tried to solve the puzzle associated with this 
phenomenon. Women diagnosed before the age of 40, typically have tumors that are less well 
differentiated, have a higher proliferating fraction as defined by the amount of Ki-67 present, and 
are more likely to have lymph node invasion  (Shannon & Smith, 2003). Other studies have 
shown women under the age of 35 have more advanced stages of the disease at diagnosis which 
contributes to a poorer 5-year survival rate (Chung, Chang, Bland, & Wanebo, 1998).  A study 
conducted by Colleoni and colleagues, sought to evaluate the pathological features and staging of 
breast cancer in premenopausal women recently diagnosed with invasive breast cancer and  
referred to surgery. Researchers concluded that women under 35 were more like to have tumors 
classified as lacking the estrogen and progesterone receptors. These tumors are also had a high 
Ki-67 rate suggesting that the tumor is highly proliferative. These patients’ tumors were also 
high invasive (Colleoni et al., 2002).  
Once diagnosed patients and their physicians decide what is the optimal treatment based 
on the stage and biological characteristics of the tumor. Factors such as age, preference, risk and 
11 
 
benefits are taken into account before a decision is made. There are various different treatment 
options. Forms of treatment are radiation, hormone or target therapy, chemotherapy, and surgery. 
Systemic treatments (hormone therapy and chemotherapy) operate by entering the bloodstream 
and destroying or controlling the cancer in the body. Specifically, chemotherapy kills circulating 
cancer cells. Chemotherapeutics offer a greater response when combined with other drugs such 
as Doxorubicin, an anthracycline antibiotic. (Kaur, Saini, Peer, & Singh, 2010). Doxorubicin 
slows or stops the growth of cancer cells by preventing DNA replication and inhibiting protein 
synthesis. This anthracycline is commonly used in combination with Paclitaxel to treat 
aggressive breast cancers (Du et al., 2010).  The poor prognosis of triple negative breast cancer is 
due to the lack of response to chemotherapeutics, in comparison to other forms of breast cancer.  
This is also attributed to the relapse that occurs if the tumor is not completely removed initially 
(Kaur et al., 2010).  
2.2 Triple Negative Breast Cancer  
 Triple-Negative Breast Cancer (TNBC) is  a specific breast cancer phenotype; which 
lacks the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal 
growth factor-2 receptor (HER-2) (Dawood, 2010).  These receptors are expressed in normal 
breast tissue and other forms of breast cancer. Each receptor plays a role in the normal 
development of breast tissue. Estrogen plays a role in female development, and thus is 
responsible for regulation of breast growth and the menstrual cycle. During pregnancy, estrogen 
works as a regulator for progesterone production. Progesterone is secreted by the ovaries and 
works in conjunction with estrogen to regulate breast growth and the menstrual cycle. This 
hormone prevents the uterus from contracting prematurely during pregnancy. HER-2 is a surface 
protein. This protein participates in signal transduction pathways that aid in differentiation and 
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growth. The lack of these receptors contributes to the aggressiveness of triple negative breast 
cancer (Wang et al., 2011). The absence of these receptors also plays a role in the therapeutic 
challenges that are associated with triple negative breast cancer.  
 TNBC represents 15% of all breast cancers (Conte & Guarneri, 2009). Triple negative 
breast cancer prognosis is different from the other subtypes of the disease. Patients diagnosed 
with triple negative are less likely to reach the five year survival mark. The five year survival 
rate is based on the stage of the disease at diagnosis. Earlier stages of diseases have an 84% 
chance of survival during the first five years of disease, while later stages only have an 18% 
chance (Fallowfield, 2004). Triple negative breast cancer  patients are also more likely to suffer 
from metastatic recurrence within the first three years of treatment (Dent et al., 2007). Other 
characteristics associated with the poor prognosis of triple negative breast cancer are: large 
tumor sizes, poor tubule formation, high tumor grades, high mitotic index, and necrosis 
(Yamamoto & Iwase, 2010).   
 Triple negative breast cancers are characterized by aggressive clinical features such as 
onset at an early age (≤35), larger tumor sizes, and higher grades of tumors. Canadian scientists, 
Dent and colleagues evaluated prognosis in over 1,500 women. The study questioned the 
likelihood of distant recurrence and death among women with triple-negative breast cancer in 
comparison to patients with non-triple negative forms of breast cancer. The results indicated that 
women with triple negative breast cancer were more likely to develop recurrence following 
treatment within the first three years. These patients were also more like to develop brain 
metastasis (Dent et al., 2007). It is estimated that 15% of all patients diagnosed with triple 
negative breast cancer will develop brain metastasis. Once brain metastasis occurs patients have 
an average survival time of six months (Boogerd, Vos, Hart, & Baris, 1993). While triple 
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negative breast cancer is not resistant to current chemotherapeutics it is not as responsive to 
treatment as other subtypes of breast cancer. Some suggested approaches to future treatments 
include use of DNA-damaging agents, targeting receptors such as the epidermal growth factor 
receptor (EGFR) and the vascular endothelial growth factor (VEGF), and poly-ADP ribose 
polymerase inhibitors  (C. Anders & Carey, 2008).  
2.3 African-American Women and Breast Cancer  
 Breast Cancer is a major health disparity among the African-American community 
behind cardiovascular disease. It is the second leading cause of death in African-American 
women. This community is more likely to be diagnosed with aggressive forms of breast cancer in 
comparison to the Caucasian community. The triple negative tumors in African-American 
women are more likely to have a higher mitotic activity and be poorly differentiated (Jones et al., 
2004). A study conducted by Chen and associates, examined the histological characteristics of 
tumors from blacks and Caucasians. The study found that African-Americans were more likely 
to have higher mitotic activity in comparison to their Caucasian counterparts. Increased mitotic 
activity is associated with elevated levels of estrogen. Estrogen stimulates ductal epithelium and 
therefore increases the mitotic activity of the cells. This potentially suggests that African-
American women may have higher levels of estrogen which could explain their higher mitotic 
activity; however, no studies have been conducted at this time to evaluate this difference (Chen 
et al., 1994). 
 African-American women are more likely to be diagnosed with breast cancer at a 
younger age than any other ethnicity.  Several studies have shown that triple negative breast 
cancer has a higher prevalence among premenopausal African-American women (Ismail-Khan & 
Bui, 2010; Yamamoto & Iwase, 2010).  By the time of diagnosis their cancer is already in the 
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later stages of the disease. This makes it difficult to offer many treatment options for these 
patients (C. K. Anders & Carey, 2009; Reis‐Filho & Tutt, 2008; Stockmans, Deraedt, Wildiers, 
Moerman, & Paridaens, 2008).  Previously it was shown that 54% of tumors in African-
American women lack the estrogen and progesterone receptors. This causes them to be more 
vulnerable to lymphatic invasion and necrosis (Jones et al., 2004). Other factors that may play a 
role in the poor prognosis are genetic mutations and molecular alterations such as the presence of 
the BRCA1 gene. The BRCA1 gene causes patients to be more susceptible to breast cancer. The 
cause for this disparity is not fully understood at this time.  Germline mutations of the BRCA1 
tumor-suppressor gene are triple negative. These breast tumors are typically basal nature. The 
BRCA1 gene plays a role in DNA repair, transcriptional regulation, and cell cycle check point 
control (C. Anders & Carey, 2008).  
2.4 Breast Cancer Therapeutic Options 
 Options for breast cancer treatment vary depending on the staging of the disease as well 
as taking in account the patient’s age. The goal is to treat the disease while preserving the quality 
of life of the patient. Options include surgery, radiation, hormone therapy, chemotherapy, and 
target therapy. The goal of surgery is to remove the cancer from the breast. This is also seen as a 
method to evaluate the stage of the disease. Patients have the option to receive either a 
lumpectomy or a mastectomy. Lumpectomies only remove cancerous tissue from the breast, 
while mastectomies are the complete removal of the breast (Veronesi et al., 2002). Radiation can 
be given either externally or internally. External beam radiation is given over a course of 6 
weeks. Internal radiation is also known as brachytherapy. Brachytherapy uses radiation seeds 
sent to the localized area of the disease to directly target the cancer (Beitsch, Shaitelman, & 
Vicini, 2011).  
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 Systemic therapy uses anti-cancer drugs, which can be administered via injection or 
orally. This allows the medication to enter the bloodstream and flow throughout all parts of the 
body. This form of therapy includes three components: targeted therapy, chemotherapy, and 
hormone therapy. Each component has a different mechanism allowing it to be more effective 
than another depending on the staging of the disease. Targeted therapy focuses on attacking 
specific parts of cancer cells, chemotherapy attacks cancer cells, and hormone therapy works to 
block the natural hormones of the body such as estrogen (Mauri, Pavlidis, & Ioannidis, 2005). 
While these drugs and treatments are sometimes very effective they do not always preserve the 
quality of life for the patient. Researchers are beginning to examine other treatment options 
which may increase the quality of life for patients.  
2.5 Cancer and Natural Therapeutics  
  Due to the adverse side effects associated with conventional therapeutic options, it is 
beneficial to examine alternative methods of treatment to assist in preserving the patients’ quality 
of life. The use of plants as a cancer therapeutic has a long history, by playing an important role 
in anti-cancer agents. Over 60% of anti-cancer agents were derived from natural sources such as 
plants, marine organisms and micro-organisms (Cragg & Newman, 2005).  Anti-cancer drugs 
such as Paclitaxel and Doxorubicin are synthesized from natural products. Paclitaxel is derived 
from the taxol extracts of the English yew tree, Taxus. This therapeutic is currently used to treat 
ovarian, breast and other cancers. Paclitaxel functions by promoting tubulin assembly and 
inhibiting cell proliferation. Doxorubicin, an anthracyclin antibiotic, damages DNA by 
intercalation. This therapeutic is derived from the bacteria Streptomyces peucetius (Reddy et al., 
2003). 
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It is believed that oxidative damage to DNA plays a role in the formation of cancer. Cells 
that divide with damaged DNA, lead to genetic alterations leading to the beginning phases of 
cancer. The mechanism of antioxidants found in fruits and vegetables appear to be beneficial in 
the earlier stages of cancer (Reddy et al., 2003). The complete mechanism causing this effect is 
unknown; however, previously it has been shown that antioxidants can lower the incidence in 
several forms of cancer. The active ingredient α- and β-carotene found in carrots has shown 
inhibition of pancreatic, colon, and breast cancer by enhancing the chemotaxis ability of 
macrophages (Cheng, Shen, Fei Pang, & Chen, 2001).  
 The lycopene of tomatoes are associated with a lower risk of cancers such as lung, 
stomach and prostate cancer. There is a suggestion that this effect may be seen in cervical, breast 
and oral cancer as well. As a carotenoid, lycopene has not proven to offer a direct benefit on its 
own however it is believed that other compounds found in the tomatoes may interact with 
lycopene. It is believed that lycopene functions by limiting cellular macromolecule damage from 
reactive oxygen species; however, other mechanisms are possible. Knowledge relating the 
properties of lycopene are poorly understood on a pharmacological view (Giovannucci, 1999). 
While the mechanism related to the protective effects of antioxidants are not fully understood is 
appears that antioxidants have the ability to reduce genetic instability in cancer cells (Reddy et 
al., 2003). 
2.6 Rosehip Extracts 
Rosehip is the fruit of the rose plant that ranges in color from red to orange; however, 
there are some species whose color ranges from dark purple to black. Rosehip extracts have been 
used as chemopreventive agents due to their mechanistic actions on cancer cells. The elevated 
levels of lycopene found in rosehip extracts are associated with increased apoptosis in prostate 
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cancer (Amin et al., 2009).   Rosehip fruits have shown potent anti-proliferative activity against 
colon, breast, and cervical cancer cells in vitro. Rosehips are high in vitamin C (Tumbas et al., 
2011) causing this pseudo fruit to be rich in ascorbic acid, phenolic components, and carotenoids 
(Chrubasik et al., 2008). These high antioxidant contents cause rosehips to have high antioxidant 
activities. Studies have shown that it is useful in treating arthritis due to its anti-inflammatory 
and anti-oxidant effects (Andersson et al., 2011). These dietary antioxidants may contribute to 
the protection of biologically important cellular components. Antioxidants function by reacting 
with free oxygen radicals and action as reducing agents to induce production of anti-oxidative 
enzymes. This contributes to the inhibitory capacity against cell proliferation caused by these 
antioxidants (Su et al., 2007).  Studies have shown that the Vitamin C and flavonoids found in 
rosehips are responsible for the antioxidant activity associated with rosehip products (Wang et 
al., 2011). However, it is the polyphenols found within this plant that is responsible for the anti-
proliferative activity (Wang et al., 2011). The anti-proliferative effects on cell proliferation in 
African-American triple negative breast cancer have not yet been tested.   
2.7 Phosphatidylinositol 3-Kinase-AKT and Mek/Erk Pathways  
Carcinogenesis is a complex multi-step process associated with abnormal proliferation in 
an unrestricted manner. This is due to an  imbalance between growth promoting and growth 
inhibiting mechanisms (HemaIswarya & Doble, 2006). Components of the phosphatidylinositol 
3-Kinase-AKT signaling pathway are deregulated in different human cancers. This deregulation 
is prevalent in breast cancer and can be seen by the presence of elevated AKT 1 kinase activity, 
AKT2 amplification, and overexpression of PI3K and AKT2. The activity of this pathway is 
functionally associated with the transformation of viral oncogenes such as the sarcoma viral 
oncogene (Src). This pathway is responsible for cellular processes such as cell proliferation, 
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growth, apoptosis, and cytoskeletal rearrangement. One component that is deregulated within the 
PI3K pathway is the p70 S6 kinase. The p70 S6 kinase regulates the multiple phosphorylation 
sites of 40 S ribosomal protein in vivo. The activity of p70 S6 kinase is controlled by multiple 
phosphorylation events located within the catalytic, linker and pseudosubstrate domains. This 
mitogen is required for cell growth and G1 cell cycle progression (Pullen & Thomas, 1997). The 
intracellular catalytic domain of HER-2 receptor can be phosphorylated by the formation of 
homodimeric and heterodimeric kinase active-complexes. This then leads to the activation of 
signaling pathways, such as PI3K/AKT and MAPK,  that promote proliferation or survival of 
breast cancer cells (Chang H Song, 2010).  The mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) are two major pathways involved in proliferation and 
survival. Mitogens within the MEK/ERK signaling pathway function by transmitting signals 
from receptors to regulate gene expression and can also play a role in the prevention of 
apoptosis. This pathway interacts with the PI3K pathway to regulate growth in forms of 
tumorigenesis (McCubrey et al., 2006).  AKT, p70 S6 kinase, and ribosomal protein s6 are 
among the most important of the downstream molecules found in these pathways (Chang H 
Song, 2010).  By understanding the effect that rosehip extracts have on this mitogen it is possible 
to explore the usefulness of this extracts as a potential alternative treatment option for aggressive 
breast cancers such as triple negative breast cancer.  
2.8 Research Objectives 
 The objective of this thesis was to investigate the effects of crude rosehip extracts on cell 
proliferation in African-American breast cancer cell lines, and to identify the signaling pathways 
responsible for those effects. It was hypothesized that crude rosehip extracts inhibit cell 
proliferation and cell migration in triple negative breast cancer cells at appropriate concentration 
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levels by blocking the AKT and Mek/Erk1/2 signaling pathways. Previous studies have shown 
that rosehips possess a large amount of phytochemicals which have the ability to prevent cell 
proliferation in breast (MCF-7), colon (HT-29) and cervical cancer cell lines (Olsson, 
Gustavsson, Andersson, Nilsson, & Duan, 2004; Su et al., 2007; Tumbas et al., 2011). It is 
suggested that the anti-cancer effects of rosehip extracts are related to the antioxidant and anti-
proliferative nature of the extracts (Olsson et al., 2004; Tumbas et al., 2011). Another study 
being conducted  in our laboratory demonstrated that rosehip extracts are able to prevent cell 
proliferation in glioblastoma cells by decreasing phosphorylation in AKT and MAPK signaling 
(Cagle et al., 2012).  Based on this knowledge this study was designed to examine the effects in 
breast cancer cell lines.  
 The work within this thesis had the following objectives: 1) determine the effect of 
rosehip extracts on cell proliferation in African-American breast cancer cell lines; 2) identify 
signaling pathways responsible for mediating rosehip extract effects on cell proliferation in 
African-American breast cancer cell lines; 3) Examine whether the efficacy of Doxorubicin, a 
known breast cancer chemotherapeutic, is increased when cells are pre-treated with rosehip 
extracts. There is limited knowledge associated with the effects of rosehip extracts in African-
American breast cancer cell lines. This thesis investigated the physiological and molecular 
mechanisms associated with the effect of rosehip extracts to assist in understanding the 
functional role of these extracts, potentially leading to a homeopathic therapeutic option for 
aggressive breast cancer subtypes. 
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CHAPTER 3 
Methodology 
3.1 Breast Cancer Cell Lines 
Human luminal breast cancer cell lines (LBC): HCC1500, HCC70 and the triple negative 
breast cancer (TNBC): HCC1806, MB157 were acquired from the American Type Culture 
Collection (ATCC) (Table 3.1). HCC70 is a luminal A breast cancer cell line isolated from a 49 
year old African-American woman. This poorly differentiated epithelial cell line overexpresses 
p53 oncogene but does not express Her2-neu oncogene; and is positive for estrogen receptor 
(ER) but negative for the progesterone receptor (PR). This cell line was established from a 
primary, stage IIIA, grade 3, invasive ductal carcinoma with lymph node metastasis.  HCC1500 
is a luminal A cell line from a 32 year old African-American woman with a stage IIB, grade 2 
invasive ductal carcinoma tumor. Established in 1995, this cell line doesn’t express Her2-neu but 
expresses p53 oncogene. This patient had a family history of early-onset colon cancer and had a 
sister with breast cancer.  
HCC1806 is a triple negative breast cancer cell line isolated from a sixty year old 
African-American woman. The woman had no family history of breast cancer. This cell line is 
negative for estrogen receptor, progesterone receptor, and human epithelial receptor-2. The 
tumor that these cells were derived from was stage IIB. The triple negative breast cancer cell line 
MB157 was isolated from a 48 year African-American woman with metastatic medullary breast 
cancer.  
The primary cell line AG11132 was established in 1978 during a breast reduction 
mammoplasty from a sixteen year old African-American female. The cell line is used as a model 
of non-cancerous breast tissues throughout the study.   
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Table 3.1  
Characteristics of Triple Negative and Luminal Breast Cancer Cell Lines 
Cell Line 
Estrogen 
Receptor 
Status 
Progesterone 
Receptor 
Status 
Human 
Epithelial 
Receptor-
2 Status 
p53 oncogene 
Status 
Her2/neu 
oncogene 
Status 
Subtype 
HCC70 Positive  Negative  Negative Positive/ 
Overexpression 
Negative Luminal 
A 
HCC1500 Positive Positive Negative Positive  Negative  Luminal 
A 
HCC1806 Negative  Negative  Negative  Negative  Negative TNBC 
MB157 Negative  Negative  Negative  Negative Negative TNBC 
 
3.2 Breast Cancer Cell Culture Conditions 
 Breast cancer cell lines were incubated at 37°C in 5% CO2. The cell lines (HCC70, 
HCC1500, and HCC1806) were grown in RPMI media supplemented with 10% Fetal Bovine 
Serum (FBS) and penicillin-streptomycin (100unit/µl). MB157 were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% FBS and penicillin-streptomycin. 
AG11132 were grown in Mammary Epithelial Cell Growth Medium (MEGM) (Lonza, 
Switzerland) without serum. Upon confluency, each cell line was passed with TrypLE Express 
(Gibco, New York). Each cell line was passed for 30 passages before a new aliquot was thawed 
and  
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3.3 Plant Material and Preparation of Crude Extracts   
 Dried Rosehip calyces and crude Rosehip extracts were a kind gift from Dr. Ipek 
Goktepe (North Carolina A&T State University). Freeze dried calyces were grounded to powder. 
After grinding, powdered material will be kept in a -20°C freezer until further use. The Rosehip 
powder was soaked in 10% deionized water, 80% ethanol (1:5 w/v) or 80% methanol (1:5 w/v) 
and sonicated for 20 minutes with continual nitrogen gas purging. Extracts were filtered through 
Whatman No. 2 filter paper and evaporated to dryness under reduced pressure. The Rosehip 
extracts were stored at -20ºC. The rosehip extracts appear reddish-orange at the end of the 
process. The residues of the crude extracts were tested in human breast cancer cell lines for 
cellular anti-proliferative activity.  
3.4 Colorimetric Cell Proliferation Rate and Viability (MTT) Assay 
 In order to test the rate of cell proliferation MTT assays were performed. Prior to 
treatment 10,000 cells were plated per well in a 96 well plate and allowed to reach 70-80% 
confluency overnight. Treatments were prepared by reconstituting the rosehip extracts in m 
RPMI or DMEM media plus serum.. Cells were treated with various concentrations of rosehip 
extract (1mg/ml, 250ug/ml, 25 ug/ml and 25 ng/ml) for 48 hours in medium (RPMI plus 10% 
FBS.) Cells were also treated with U0126 (MEK1/2 inhibitor, Cell Signal: Massachusetts) and 
LY294002 (PI3 Kinase inhibitor, Cell Signal: Massachusetts). Wells without cells were given 
rosehip treatments to be used as a background.  Following treatment, 0.01mL of 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrasodium bromide (MTT) plus PBS, pH of 7.4 was added to 
each well. Wells were incubated at 37°C in 5% CO2 for 4 hours in order for MTT cleavage to 
occur. Isopropanol (0.1mL) with 0.4 N HCL was then added and mixed thoroughly to aid in 
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absorbance measurement. After 1 hour, growth was measured through absorbance measurement 
with an ELISA plate reader at two wavelengths of 570nm and 630nm.  
3.5 Western Blot Analysis 
 Cells in a 6 well plate were exposed to varying rosehip concentrations(1mg/ml, 
250µg/ml, 25µg/ml and 25ng/ml) for 48 hours. Cell lysates of the exposed cultureswere 
extracted with 1% Triton X-100 and 0.2% Nonident P-40 in the presence of protease cocktail 
inhibitors. Lysates containing proteins were then separated by SDS-PAGE using 10% 
polyacrylamide gels. Proteins were then transferred to Polyvinylidene Fluoride (PVDF) 
membrane and blocked in 5% milk in TBS-T for one hour.  The PVDF membrane was incubated 
with primary antibody overnight at 4°C while shaking. The primary antibody was specific for 
phospho-p70 S6 kinase, total p70 S6, phospho-p90RSK, phospho-Akt, total Akt, phosphor-
p44/42 MAPK (Erk1/2), and phospho-S6 (Cell Signal: Massachusetts).  Rab11 and β-tubulin 
were used as loading controls.  The antibodies were diluted in 5% milk in TBS-T, phospho-
p90RSK, phosphor-Akt, phospho-p44/42 MAPK (Erk1/2), phospho-S6 ribosomal protein, Rab11 
at 1:200; Total Akt at 1:1000, total p70 S6 at 1:1000, and phospho-p70 S6 kinase at 1:1000. β-
tubulin was diluted in 5% milk in PBS containing Tween 20 at 1:5000 dilution. Membranes were 
then washed in TBS-T three times for 10 minutes. The membrane was incubated with secondary 
antibody, anti-rabbit, diluted in 5% TBS-T for one hour. The membrane was washed three times 
for 10 minutes in TBS-T (washed in PBS containing Tween 20 when probed for β-tubulin). 
Electrochemiluminescence (ECL) (Thermo Fisher Scientific: Illinois) substrate was then applied 
before wrapping the membrane in transparent plastic wrap and exposed to x-ray film. The x-ray 
film was developed to evaluate protein bands.  
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3.6 Statistical Analysis 
 Statistical analysis was conducted on experiments examining cell proliferation using cell 
proliferation assays. Experiments were averaged and means and standard deviation from three 
individual experiments were analyzed for statistical significance (P <0.001) using a one-tailed 
Analysis of Variance (ANOVA) and the Newman-Kuels multiple comparison post-test.  Bars 
labeled with the same letter are not statistically different (p>0.001).  
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CHAPTER 4 
Results 
The goal of this research was to investigate the effects of crude rosehip extracts on 
African-American Breast Cancer cell lines and investigate the cell signaling pathways associated 
with these effects. The study compared the effect of crude rosehip extracts (rosehip methanol, 
rosehip ethanol, and rosehip water) in African-American triple negative breast cancer cell lines 
(HCC1806 and MB157) and luminal breast cancer cell lines (HCC70 and HCC1500). The 
primary tissue (AG11132) was used as a model of non-cancerous breast tissue. Previous studies 
have shown that rosehip extracts decrease proliferation in various types of cancer (Cagle et al., 
2012; Fujii & Saito, 2009), however the effect on breast cancer, specifically, triple negative 
breast cancer has not yet been studied. Therefore, we hypothesized that crude rosehip extracts 
will decrease the cell proliferation in African-American breast cancer cell lines.  
4.1 Crude Rosehip Extracts Decrease Cell Proliferation in Breast Cancer Cell Lines 
 In this set of experiments, the effect of crude rosehip extracts on the proliferation of 
breast cancer cells was examined using MTT assays in five cell lines (HCC70, HCC1500, 
HCC1806, MB157 and AG1132). Cells were treated for 48 hours with the following controls: 
serum starved, plus serum and known cell proliferation inhibitors LY294002 (blocks the AKT 
signaling pathway) and U0126 (blocks the MAPK signaling pathway).  Each of the breast cancer 
cell lines were assayed following treatment with vary concentrations of rosehip extracts 
(1mg/ml, 250µg/ml, 25µg/ml and 25ng/ml). Rosehip extracts were prepared in methanol, 
ethanol, or water in an effort to determine which extraction method produced more effective 
extracts.  
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The initial studies of this objective examined the effect of rosehip water extracts. These 
extracts were isolated using 10% deionized water.  The MTT (pale yellow substrate) reaction 
cleaves living cells to display a dark blue product. This process is a result of cells having active 
mitochondria which allows for the cleaving of significant amounts of MTT. The assay can be 
used to determine proliferation or complement-mediated cytotoxicity. .Following rosehip water 
treatment MTT assays were conducted to observe the relative rate of proliferation. The serum 
starved control was a control measure for the non-growth stimulation, and was seen to yield the 
lowest rate of cell proliferation. Experimental data is a representation of three experiments (n=3). 
The means and standard deviation of the experiments were analyzed for statistical significance 
(p<0.001) using a one-tailed analysis of variance and the Newman-Keuls multiple comparison 
post-test. Each sample was compared to plus serum. Samples that were statistically different 
(p<0.001) were labeled B. Samples that were not statistically different from the plus serum 
control (p>0.001) were labeled A.  The results are displayed in Figure 4.1. In the HCC70 cell 
line (Figure 4.1 A); in comparison to the plus serum positive control there was a significant 
decrease in cell proliferation. The concentrations showed a dose-dependent decrease in cell 
proliferation. In the HCC1500 cell line (Figure 4.1 B), in comparison to the plus serum positive 
control there was a significant (p<0.001) decrease in cell proliferation at the highest 
concentration of rosehip water. The highest concentration of rosehip water yielded a lower cell 
proliferation rate in comparison to the two known cell proliferation inhibitors (LY294002, 20µM 
and U0126 10µM).  
 The triple negative breast cancer cell line HCC1806 (Figure 4.1 C) showed a significant 
decrease in cell proliferation at all concentration levels of rosehip water. On the other hand 
MB157, another triple negative breast cancer cell line (Figure 4.1 D), showed a decrease in 
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proliferation; however, there was no statistical significance (p>0.001). The inhibitors LY294002 
(20µM) showed a greater decrease in cell proliferation than the varying concentrations of rosehip 
water.  
 
Figure 4.1 Effect of Rosehip Water on Breast Cancer Cell Lines. 
 The second phase of objective1 examines the effect of rosehip ethanol extracts in the 
breast cancer cell lines (Figure 4.2). In the HCC70 cell line (Figure 4.2 A), in comparison to the 
plus serum control rosehip ethanol at the two higher concentrations (1mg/ml and 250µg/ml) 
decreased cell proliferation. The highest concentration significantly decreased (p<0.001) the rate 
of cell proliferation better than the two known cell proliferation inhibitors. In the HCC1500 cell 
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line (Figure 4.2 B), the highest concentration of rosehip ethanol had the greatest effect in 
decreasing cell proliferation. The triple negative breast cancer cell lines HCC1806 and MB157 
(Figure 4.2 C & D respectively) showed a significant decrease (p<0.001) of cell proliferation at 
all concentrations of rosehip ethanol.  
 
Figure 4.2 Effect of Rosehip Ethanol on Breast Cancer Cell Lines. 
 The third phase of this objective examines the effect of Rosehip methanol in the breast 
cancer cell lines. In the luminal breast cancer cell lines HCC70 (Figure 4.3 A) and HCC1500 
(Figure 4.3 B), in comparison to the plus serum control rosehip methanol significantly decreased 
(p<0.001) the rate of cell proliferation in dose-dependent manner with the greatest effect being 
seen in the highest concentration.  In the triple negative breast cancer cell line HCC1806 (Figure 
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4.3 C), in comparison to the plus serum control rosehip methanol extracts significantly decreased 
(p<0.001) the rate of cell proliferation in a dose-dependent manner with the highest 
concentration presenting a cell proliferation rate lower than the minus serum control. In the 
MB157 cell line (Figure 4.3 D); in comparison to the plus serum control all concentrations of 
rosehip methanol decreased the rate of cell proliferation. These concentrations decreased the rate 
of proliferation to a rate lower than the minus serum control and the two known inhibitors. This 
suggests a potentially toxic effect of the rosehip extracts in the breast cancer cell lines.   
 
Figure 4.3 The Effect of Rosehip Methanol Extracts on Breast Cancer Cell Lines. 
 The final phase of objective one examined the effect of rosehip extracts sonicated in the 
presence of methanol. Rosehip methanol extracts demonstrated a significant decrease (p<0.001) 
in each of the breast cancer cell lines at each of the varying concentrations. In the luminal breast 
cancer cell lines and the HCC1806 triple negative breast cancer cell line the rosehip extract-
mediated decrease occurred in a dose-dependent manner. In order to determine whether rosehip 
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extracts were detrimental to normal breast cells, treatments were administered to the AG11132 
primary cell line to determine the effect on cell proliferation rate (Figure 4.4). In this preliminary 
experiment, the effect of rosehip methanol extracts was examined to give a model of non-
cancerous breast tissue. The rosehip methanol extracts significantly decreased (p<0.001) the rate 
of cell proliferation in the three higher concentrations (1mg/ml, 250µg/ml and 25µg/ml). The 
two higher concentrations caused a decrease in proliferation lower than the two known cell 
proliferation inhibitors. 
 
Figure 4.4 Effect of Rosehip Methanol on AG11132 Primary Cell Line. 
4.2. Rosehip Extracts Induce Apoptosis in HCC1500 Breast Cancer Cell line at the Higher 
Concentrations 
 Previously it has been shown that rosehip extracts decrease cell proliferation without 
inducing apoptosis in glioblastomas (Cagle et al., 2012). In order to determine if the rosehip 
methanol extracts induced apoptosis in the breast cancer cell lines western blot analysis was 
conducted to examine the amount of poly(ADP-ribose) polymerase (PARP) cleavage expression.  
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PARP is a critical component within cell signaling which is responsible for post-translational 
modifications of proteins. This occurs are a response to various different agents. PARP is 
important for regulation cellular processes such as DNA repair, cell death, and chromatin 
functions or genomic stability. There are large amounts of PARP found in the nucleus. When 
PARP becomes cleaved the cell begins to undergo programmed cell death known as apoptosis. 
Each cell line was treated with the varying concentration of rosehip methanol (1mg/ml, 
250µg/ml, 25µg/ml and 25ng/ml), the minus and plus serum control, the two known cell 
proliferation inhibitors LY294002 (20µM) and U0126 (10µM), and Staurosporine (1µM). 
Staurosporine is a chemical used to induce apoptosis in cells. Western blot analysis was 
conducted on the two luminal breast cancer cell lines (HCC70 and HCC1500) and the triple 
negative breast cancer cell line (HCC1806) (Figure 4.5). The results demonstrated that at the two 
higher concentrations there was PARP cleavage seen in the HCC1500 cell line. The HCC70 and 
HCC1500 cell line did not display any PARP cleavage. The primary cell line AG11132 showed a 
decrease in cell proliferation when treated with rosehip methanol extracts (Figure 4.4). Western 
blot analysis was conducted to compare rosehip methanol extracts to Staurosporine. The was no 
PARP cleavage in any of the rosehip concentrations, suggesting rosehip methanol does not 
induce apoptosis (Figure 4.6).  
4.3 Rosehip Methanol Extracts Decrease Phosphorylation of the AKT Cell Signaling 
Pathway and MAPK Protein  
 It was previously shown that in glioblastomas rosehip extracts decrease cell proliferation 
by inhibiting the MAPK and AKT Pathways (Cagle et al., 2012). In order to determine if these 
cell signaling pathways were responsible for the decrease in cell proliferation associated with 
rosehip methanol treatment, western blot analysis was conducted. Two luminal breast cancer cell 
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lines (HCC70 and HCC1500 and one triple negative breast cancer cell line (HCC1806) were 
treated with the varying concentrations of rosehip methanol and known inhibitors of the AKT 
and MAPK pathways. 
 
Figure 4.5 Induction of Apoptosis in Breast Cancer Cell lines. 
 
Figure 4.6 Induction of Apoptosis in AG1132 Primary Cell Line. 
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AKT is the survival pathway responsible for cellular responses such as cell proliferation, growth, 
and apoptosis (Pullen & Thomas, 1997). The MAPK signaling pathways functions by 
transmitting signals from receptors to regulate gene expression and can also play a role in the 
prevention of apoptosis. This pathway interacts with the PI3K pathway to regulate growth in 
forms of tumorigenesis (McCubrey et al., 2006). 
 In the HCC70 cell line rosehip methanol decreased phosphorylation of AKT in all 
concentrations of rosehip methanol (Figure 4.7). When examining the phosphorylation of 
p70S6K, which is downstream from AKT, all the concentrations of rosehip methanol decreased 
phosphorylation at this level, suggesting that p70S6K may be where rosehip methanol is 
targeting. When examining the MAPK cell signaling pathway, rosehip methanol treated cells 
showed a decreased in phosphorylation at all concentrations of rosehip methanol (Figure4.7).  
In the HCC1500 cell line (Figure 4.8), there was a decrease in phosphorylation of cell 
pathway members with the highest concentration of rosehip methanol. Phosphorylation of 
p70S6K was decreased at all concentrations of the rosehip methanol. This was confirmed by the 
decreased phosphorylation of S6 which is a downstream target of p70S6K. This suggests that 
p70S6K may be the targeted protein within this cell signaling pathway. The MAPK signaling 
pathway also showed decreased phosphorylation at the two higher concentrations when treated 
with rosehip methanol (Figure 4.8). Together these data demonstrate that both the AKT and 
MAPK signaling pathways are being regulated following exposure to rosehip extracts. (Figure 
4.8)  
Data in these figures (Figure 4.7 and 4.8) show that decreases in the phosphorylation 
states of key protein kinases (p70s6K and MAPK) correlates with decreases in cell proliferation 
observed in HCC70 and HCC1500 cell lines (Figure 4.3 A and Figure 4.3 B).  
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Figure 4.7 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK Signaling 
in HCC70 Cells. 
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Figure 4.8 Inhibitory Effect of Rosehip Methanol Extract Concentration AKT and MAPK 
Signaling in HCC1500 Cells. 
In the triple negative breast cancer cell line (Figure 4.9) a decrease in phosphorylation 
was seen at the highest concentration of rosehip methanol. When examining the phosphorylation 
of the S6 protein there was a decrease in phosphorylation in all concentrations in a dose-
dependent manner. As the concentrations of rosehip methanol decreased the phosphorylation of 
the S6 protein increased. The data shows a correlation with the decrease in cell proliferation 
observed in HCC1806 cell lines (Figure 4.3 C).  
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Figure 4.9 Inhibitory Effect of Rosehip Methanol Extract Concentration on AKT and MAPK 
Signaling in HCC1806 Cells. 
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In a preliminary attempt to examine the effect of rosehip methanol extracts on the 
molecular signaling of the primary cell line AG11132 western blot analysis was conducted as 
well. At the highest concentration of rosehip methanol there was an increase in the 
phosphorylation of AKT (Figure 4.10).  There was a decrease in proliferation seen when these 
cells were treated with rosehip methanol (Figure 4.4). This suggests that while cell proliferation 
is being decreased following treatment with rosehip methanol extracts the cells are switching on 
their survival mechanism in an attempt to survive the effects of the treatment.  
 
 
 
Figure 4.10 Rosehip Methanol Extracts Increase the Phosphorylation of AKT Protein in 
AG11132 Cells. 
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4.4 Rosehip Extracts Have a Potential Synergistic Effect in Cell Lines Lacking the 
Progesterone Receptor 
 In an attempt to better understand the potential of rosehip extracts as a homeopathic 
remedy against breast cancer cell lines, experiments were designed to determine whether the 
anti-proliferative capacity of rosehip extracts compared to that of Doxorubicin.  The first part of 
this objective was to determine which concentration would best work with the breast cancer cell 
lines (HCC70, HCC1500, and HCC1806) within this study. Previous studies have used 
Doxorubicin at concentrations such as 1µM, 5µM and 10µM for 24 hours in 4T1 breast cancer 
cell line. (Du et al., 2010). Based on these studies we examined those concentrations to 
determine which would give the best effect in the two luminal breast cancer cell lines (HCC70 
and HCC1500) and the triple negative breast cancer cell line (HCC1806) (Figure 4.11). In this 
preliminary study, the two luminal breast cancer cell lines Doxorubin at a 5µM concentration 
showed a greater decrease in cell proliferation in comparison to the plus serum control (Figure 
4.11 A & B). However in the triple negative breast cancer cell line HCC1806 the greatest 
decrease in cell proliferation was yielded at the 10µM concentration of Doxorubin (Figure 4.11 
C). Based on these findings we decided to increase the concentration to 20µM in order to 
examine the effects of doxorubicin when combined with rosehip methanol.  
Studies are beginning to combing the use of herbs and plant extracts with conventional 
drugs for several reasons. Presently the cost of health care, drug prices and the number of 
patients are constantly increasing which play a role in the increasing interest in developing 
phytomedicines that can be combined with current therapeutics (HemaIswarya & Doble, 2006). 
Previously studies have shown that natural products such as curcumin have a synergistic effect 
when combined with Doxorubicin (HemaIswarya & Doble, 2006; Notarbartolo et al., 2005). This  
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Figure 4.11 Effect of Doxorubicin on Breast Cancer Cell Lines. 
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knowledge was the basis of the design for the second part of this objective. In this preliminary 
study breast cancer cell lines (HCC70, HCC1500 and HCC1806) were exposed to the following 
treatments: 1) 1mg/ml rosehip methanol (48 hours), 2) 20µM Doxorubicin (48 hours), 3) 
pretreated with 1mg/ml Rosehip Methanol (24 hours) and then treated with 20µM Doxorubicin 
(24 hours), 4) Treated with 1mg/ml Rosehip Methanol and 20µM Doxorubicin simultaneously 
(48hours).  
 
Figure 4.12 Effect of Rosehip Methanol Versus Doxorubicin. 
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The minus serum control yielded the lowest rate of proliferation therefore each treatment was set 
relative to this.  Each cell line responded differently to the specific treatments. In the HCC70 cell 
line (Figure 4.12 A); the lowest yield in cell proliferation rate was when the cells were pretreated 
with the 1mg/ml rosehip methanol.  In the HCC1500 cell line (Figure 4.12 B), the 1mg/ml 
rosehip methanol treatment presented the lowest yield. In the triple negative breast cancer cell 
line, HCC1806, (Figure 4.12 C) there were similar yields with the 1mg/ml rosehip methanol 
treatment and the pretreatment option. Both of these treatments presented the lowest yield in 
comparison to the plus serum control.  
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CHAPTER 5 
Discussion and Future Research 
Triple negative breast cancer is associated with an aggressive nature due to their lack of 
specific receptors. Due to this problem it is imperative that effective preventive and therapeutic 
ventures be explored with this disease (Irvin Jr & Carey, 2008). The objective of this thesis was 
to investigate the effects of crude rosehip extracts on cell proliferation in African-American 
breast cancer cell lines, and to identify the signaling pathways responsible for those effects. It 
was hypothesized that crude rosehip extracts inhibit cell proliferation and cell migration in triple 
negative breast cancer cells at appropriate concentration levels by blocking the AKT and 
Mek/Erk1/2 signaling pathways. Previous studies have shown that rosehips possess a large 
amount of phytochemicals which have the ability to prevent cell proliferation in breast (MCF-7), 
colon (HT-29) and cervical cancer cell lines (Olsson et al., 2004; Su et al., 2007; Tumbas et al., 
2011). It is suggested that the anti-cancer effects of rosehip extracts are related to the antioxidant 
and anti-proliferative nature of the extracts (Olsson et al., 2004; Tumbas et al., 2011). Another 
study demonstrated that rosehip extracts are able to prevent cell proliferation in glioblastoma 
cells by decreasing phosphorylation  in AKT and MAPK signaling (Cagle et al., 2012).  Based 
on this knowledge this study was designed to examine the effects in breast cancer cell lines.  
5.1 Determined the Effect of Crude Rosehip Extracts on Breast Cancer Cell Line 
Proliferation 
 The first specific aim set out to determine the effect of crude rosehip extracts on luminal 
breast cancer cell lines, triple negative breast cancer cell lines, and a primary breast cell line. The 
study was able to identify that all extraction methods of rosehip (rosehip water, rosehip ethanol, 
and rosehip methanol) were able to decrease the cell proliferation rate at the highest 
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concentrations (1mg/ml). Further investigation showed that this effect occurs without toxicity 
and inducing apoptosis in breast cancer cell lines. In the primary cell line there was also a 
decrease in cell proliferation when treated with rosehip methanol. These results were similar to 
those presented in a study which examined the effect of rosehip extracts on glioblastomas (Cagle 
et al., 2012) 
5.2 Determined Signaling Pathways Effected in Breast Cancer Cell Lines by Crude 
Roseship Methanol Extracts  
 Previous studies demonstrated that the decrease of cellular proliferation in glioblastomas 
was associated with a decrease in phosphorylation along the MAPK and AKT cell signaling 
pathways (Cagle et al., 2012). The study was able to determine the AKT pathway was regulated 
by treatment with rosehip methanol extracts in the luminal and triple negative breast cancer cell 
lines. It was suggested in the data that rosehip methanol may target the p70S6K phosphorylation 
more specifically. However, it was seen that the primary cell line AG11132 displayed an 
increase in AKT phosphorylation suggesting that while cell proliferation is decreased when 
treated with rosehip methanol, the survival pathway associated with AKT may be in effect in this 
cell line. Further study of the signaling pathways in the primary cell line can assist in explaining 
the difference that is observed.  
5.3 Determined a Potential Synergistic Effect with Doxorubicin and Rosehip Methanol 
Extracts in Breast Cancer Cell Lines Lacking the Progesterone Receptor 
 Previous studies have shown that natural products such as curcumin have a synergistic 
effect when combined with doxorubicin (HemaIswarya & Doble, 2006). Based on this 
knowledge this study was able to determine that rosehip methanol may have a potential 
synergistic effect with doxorubicin. However, the synergistic effect differs between the cell lines, 
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suggesting that the subtype of cancer will play a critical role in determining the efficacy of this 
extract as a potential therapeutic. In this preliminary study, there is a suggested potential 
synergistic effect in breast cancer cell lines lacking the progesterone receptor (HCC70 and 
HCC1806) (Table 5.1).   
Table 5.1  
Potential Synergistic Effect of Doxorubicin and Rosehip Methanol 
Characteristics  
  Estrogen 
Receptor 
Status 
Progesterone 
Receptor 
Status   
Human 
Epithelial 
Receptor-2 
Status  
Least amount 
of Cell 
Proliferation  
after 48 Hrs 
Subtype 
HCC70 Positive  Negative  Negative 1mg/ml RHM 
+ 20µM 
Doxorubicin  
Non-Triple 
Negative  
HCC1500 Positive Positive Negative 1mg/ml RHM   Non-Triple 
Negative 
HCC1806 Negative  Negative  Negative  1mg/ml RHM, 
1mg/ml RHM 
+ 20µM 
Doxorubicin  
TNBC 
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5.4 Future Directions  
 The present studies indicate rosehip extracts have the capacity to decrease cell 
proliferation in African-American breast cancer cell lines. In cell lines lacking the progesterone 
receptor this effect occurs without promoting apoptosis. The decrease in cell proliferation is 
associated with decreased phosphorylation of proteins within the AKT and MAPK signaling. 
This data suggests an anti-proliferative role for rosehip extracts in breast cancer cells. This data 
suggests that rosehip extracts have the potential to serve as a therapeutic option for difficult to 
treat breast cancers. In order to expand the knowledge, gained from these studies experiments 
will be designed to assist in determining cell signaling pathways associated with the decreased 
cell proliferation rates of the triple negative breast cancer cell line MB157. The preliminary data 
suggested a potential synergistic effect of Doxorubicin and 1mg/ml rosehip methanol extracts. 
Future studies will examine the role that the progesterone plays in mediating this potential 
synergistic effect. The study will also incorporate the MB157 cell line in order to determine if 
there is a similar trend in the findings related to the progesterone receptor. While this study 
focused on the rosehip methanol extracts, future studies will examine if there is a molecular 
difference between the rosehip ethanol and rosehip water extracts. Investigation of these 
differences will assist in taking steps towards determining the active ingredient within the 
rosehip extracts. These extracts will also be used to continue the tests of doxorubicin efficacy. 
The potential future studies would examine whether Doxorubicin efficacy is increased when pre-
treated with the rosehip ethanol and rosehip water extracts. The end results of this study will 
broaden the knowledge of these extracts and how they regulate breast cancer cell proliferation. 
The knowledge obtained from this and future studies will all for the efficacy of rosehip extracts 
as a potential homeopathic therapeutic option for aggressive breast cancer subtypes.  
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Appendix A: 
Relative Densitometry Values of Protein Expression 
 
Figure A.1 Relative Densitometry Values of HCC1806 AKT Protein  
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Figure A.2 Relative Densitometry Values of HCC1806 p70S6K Protein  
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Figure A.3 Relative Densitometry Values of HCC1806 S6 Protein  
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Figure A.4 Relative Densitometry Values for HCC1806 MAPK Protein  
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Figure A.5 Relative Densitometry Values for HCC1500 AKT Protein  
 
59 
 
 
Figure A.6 Relative Densitometry Values for HCC1500 p70S6K Protein  
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Figure A.7 Relative Densitometry Values for HCC1500 S6 Protein  
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Figure A.8 Relative Densitometry Values for HCC1500 MAPK Protein  
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Figure A.9 Relative Densitometry Values for HCC70 AKT Protein   
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Figure A.10 Relative Densitometry Values for HCC70 p70S6K Protein  
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Figure A.11 Relative Densitometry Values for HCC70 S6 Protein  
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Figure A.12 Relative Densitometry Values for HCC70 MAPK Protein 
.  
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Appendix B:  
Figure Legends 
Figure 4.1 Effect of Rosehip Water on Breast Cancer Cell Lines  Luminal Breast Cancer Cell 
Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806, MB157) 
were treated with rosehip water extracts, in the presence of 10% FBS for 48 hours at various 
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml).  In addition to rosehip extracts, known 
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  AKT pathway (LY 294002, 20 µM) 
were used. Each value is presented as the mean and standard deviation of three independent 
experiments. Columns of each graph represent relative values in comparison to serum-starved 
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with 
the Newman-Keuls post-test. Bars labeled with different letters are significantly different from 
one another (P<0.001). Bars labeled with the same letter are not significantly different 
(P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157 
 
Figure 4.2 Effect of Rosehip Ethanol on Breast Cancer Cell Lines Luminal Breast Cancer 
Cell Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806, 
MB157) were treated with rosehip ethanol extracts, in the presence of 10% FBS for 48 hours at 
various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml).  In addition to rosehip extracts, 
known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  AKT pathway (LY 294002, 
20 µM) were used. Each value is presented as the mean and standard deviation of three 
independent experiments. Columns of each graph represent relative values in comparison to 
serum-starved cells. Statistical analysis was conducted using a one-tailed analysis of variance 
(ANOVA) with the Newman-Kuels post-test. Bars labeled with different letters are significantly 
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different from one another (P<0.001). Bars labeled with the same letter are not significantly 
different (P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157 
 
Figure 4.3 Effect of Rosehip Methanol on Breast Cancer Cell Lines Luminal Breast Cancer 
Cell Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806) were 
treated with rosehip methanol extracts, in the presence of 10% FBS for 48 hours at various 
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml).  In addition to rosehip extracts, known 
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  AKT pathway (LY 294002, 20 µM) 
were used. Each value is presented as the mean and standard deviation of three independent 
experiments. Columns of each graph represent relative values in comparison to serum-starved 
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with 
the Newman-Kuels post-test. Bars labeled with different letters are significantly different from 
one another (P<0.001). Bars labeled with the same letter are not significantly different 
(P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157 
 
Figure 4.4 Effect of Rosehip Methanol on AG1132 Primary Cell AG11132 Primary cell line 
was treated with rosehip methanol extracts, in the presence of 10% FBS for 28 Hours at various 
concentration (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml).  In addition to rosehip extracts, known 
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  Akt pathway (LY 294002, 20 µM) 
were used. Each value is presented as the mean and standard deviation of three independent 
experiments. Columns of each graph represent relative values in comparison to serum-starved 
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with 
the Newman-Keuls post-test. Bars labeled with different letters are significantly different from 
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one another (P<0.001). Bars labeled with the same letter are not significantly different 
(P>0.001).  
 
Figure 4.5 Induction of Apoptosis in Breast Cancer Cell Lines Luminal Breast Cancer Cell 
Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806) were treated 
with rosehip metanol extracts, in the presence of 10% FBS for 48 hours at various concentrations 
(1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts, known inhibitors of the 
Erk/MAPK pathway (U-0126, 10 µM) and  Akt pathway (LY 294002, 20 µM) were used. Each 
cell line was also exposed to Staurosporine (1µM) for 3h (HCC1500) or 8h (HCC70 and 
HCC1500) to promote cell death an dPARP cleavage. Cleaved PARP is represented by the lower 
band and total PARP is represented by the lower band. A) HCC70 B) HCC1500 and  C) 
HCC1806  
 
Figure 4.6 Induction of Apoptosis in AG11132 Primary Cell Line AG11132 primary cell line 
was treated with rosehip methanol extracts, in the presence of 10% FBS for 48 hours at various 
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to the varying 
concentrations of rosehip methanol the cell line was also exposed to Staurosporine (1µM) for 
3hto promote cell death an d PARP cleavage. Cleaved PARP is represented by the lower band 
and total PARP is represented by the lower band.  
 
Figure 4.7 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK 
signaling in HCC70 cells HCC70 cells were treated with rosehip methanol in the presence of 
10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In 
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addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  
AKT pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2), 
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a 
protein loading control. Densitometry was used to determine the relative values of protein 
expression (Appendix)  
 
Figure 4.8 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK 
signaling in HCC1500 cells HCC1500 cells were treated with rosehip methanol in the presence 
of 10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In 
addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  
AKT pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2), 
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a 
protein loading control. Densitometry was used to determine the relative values of protein 
expression (Appendix)  
 
Figure 4.9 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK 
signaling in HCC1806 cells HCC1806 cells were treated with rosehip methanol in the presence 
of 10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In 
addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  
Akt pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2), 
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a 
protein loading control. Densitometry was used to determine the relative values of protein 
expression (Appendix)  
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Figure 4.10 Rosehip Methanol Extracts Increase the Phosphorylation of AKT protein in 
AG11132 cells AG11132 cells were treated with rosehip methanol in the presence of 10% FBS 
for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to 
rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and  Akt 
pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2), AKT, 
and S6 was determined by western blotting analysis. Tubulin was used as a protein loading 
control. Densitometry was used to determine the relative values of protein expression 
(Appendix)  
 
Figure 4.11 Effect of Doxorubicin on Breast Cancer Cell Lines Luminal Breast Cancer Cell 
Lines (HCC70, HCC1500) and a Triple Negative Breast Cancer cell line (HCC1806) were 
treated with Doxorubicin, in the presence of 10% FBS for 48 hours with various concentrations 
of Doxorubicin (10uM, 5µM, 1µM) In addition to Doxorubicin, known inhibitors of the 
Erk/MAPK pathway (U-0126, 10 µM) and AKT pathway (LY 294002, 20 µM) were used. A) 
HCC70 B) HCC1500 and C) HCC1806  
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Figure 4.11 Effect of Rosehip Methanol versus Doxorubicin Luminal Breast Cancer Cell 
Lines (HCC70, HCC1500) and a Triple Negative Breast Cancer cell line (HCC1806) were 
treated with rosehip methanol extracts and Doxorubicin, in the presence of 10% FBS for 48 
hours with various treatments (1mg/ml rosehip methanol, 20uM Doxorubicin, 1mg/ml rosehip 
methanol + 20µM Doxorubicin, 24h rosehip methanol, 24hr 20µM Doxorubicin) In addition to 
Doxorubicin and rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) 
and  AKT pathway (LY 294002, 20 µM) were used. A) HCC70 B) HCC1500 and C) HCC1806 
 
 
 
 
 
 
 
 
